The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

All News

Cmbio: A New Brand Unifying Global Leaders in Microbiome and Metabolomics Science
Finance

Cmbio: A New Brand Unifying Global Leaders in Microbiome and Metabolomics Science

NOV 19, 2024
Freya Biosciences Announces $10.4 Million Strategic Investment from the Bill & Melinda Gates Foundation
Finance

Freya Biosciences Announces $10.4 Million Strategic Investment from the Bill & Melinda Gates Foundation

NOV 19, 2024
Lallemand’s New R&D Laboratories: An Exclusive Interview with Sylvie Binda, VP of R&D
Editor's Choice

Lallemand’s New R&D Laboratories: An Exclusive Interview with Sylvie Binda, VP of R&D

NOV 15, 2024
Quadram Institute announces Professor Daniel Figeys as new Director and Chief Executive
Pharma & Human Health

Quadram Institute announces Professor Daniel Figeys as new Director and Chief Executive

NOV 12, 2024
EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis
Pharma & Human Health

EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis

NOV 11, 2024
Updates from MaaT Pharma’s Early Access Program Demonstrate Prolonged Long-Term Survival in Patients Receiving MaaT013
Oncology

Updates from MaaT Pharma’s Early Access Program Demonstrate Prolonged Long-Term Survival in Patients Receiving MaaT013

NOV 8, 2024
Researchers hope to develop novel drugs for gastrointestinal disorders by fermenting feces
Gastrointestinal

Researchers hope to develop novel drugs for gastrointestinal disorders by fermenting feces

NOV 7, 2024
Cerillo Introduces First Standardized Co-Culture System Revolutionizing Microbial Interaction and Isolation Studies
Pharma & Human Health

Cerillo Introduces First Standardized Co-Culture System Revolutionizing Microbial Interaction and Isolation Studies

OCT 24, 2024
Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims
Biotics and Supplements

Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims

OCT 22, 2024
Precision metagenomics: a rapid solution for identifying and characterizing microbial agents of infectious disease.
Editor's Choice

Precision metagenomics: a rapid solution for identifying and characterizing microbial agents of infectious disease.

OCT 17, 2024
Sequential Launches Industry-First Microbiome Target Panels for Skin Conditions
Pharma & Human Health

Sequential Launches Industry-First Microbiome Target Panels for Skin Conditions

OCT 16, 2024